Biofarma S.r.l. (“Biofarma Group”), the largest global CDMO solely focused on nutraceuticals, controlled by Ardian together with the Scarpa and the Luhadia families, announces that CEO Gianfranco Nazzi has decided to step down from his position to pursue other professional opportunities.

Over the last couple of years, the company has seen significant growth, including the transformational acquisition of US Pharmalab, which allowed the Group to significantly strengthen in the US market, thus transforming from a European to a global leader. Gianfranco Nazzi's contribution has been instrumental in steering Biofarma through a transformative period, and the Board expresses its deep gratitude for his contributions.

Germano Scarpa, founder of Biofarma and Chairman of the Board, will lead the company until a new CEO is appointed by the Board of Directors. Scarpa brings over 30 years of experience in the sector and a deep understanding of the company's mission and values. The company will continue to focus on its growth plan, with significant investments planned to expand its technological portfolio and enhance service quality for clients.

"We are grateful for Gianfranco’s dedication and contribution, which positions Biofarma well for continued success. We remain fully committed to supporting the Group and are optimistic about our ambition to create the global leader in the field.” said Giacomo Forti, Director at Ardian.

Gianfranco Nazzi also shared his thoughts on the transition: "It has been an honor to lead Biofarma and work with such a talented team. I am proud of what we have accomplished together and I am confident that Biofarma will continue to thrive."